Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: A DISCOVERY study

Clinical Therapeutics

Volumn 26, Issue 11, 2004, Pages 1821-1833

  Strandberg, Timo E ^a   Feely, John ^b   Sigurdsson, Emil L ^c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b ST JAMES S HOSPITAL   (Ireland)

^c Solvangur Health Care Centre   (Iceland)

Author keywords

atorvastatin cardiovascular disease coronary heart disease low density lipoprotein cholesterol rosuvastatin triglycerides

Indexed keywords

ATORVASTATIN; DICLOFENAC; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DEMOGRAPHY; DIET RESTRICTION; DIETARY INTAKE; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; FEMALE; HEADACHE; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MELENA; MULTICENTER STUDY; MYALGIA; NAUSEA; PATIENT COUNSELING; PATIENT SELECTION; PEPTIC ULCER; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; VOMITING;

CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; SULFONAMIDES; TRIGLYCERIDES;

EID: 11844302289     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2004.11.015     Document Type: Article

References (37)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
2. Wood D., De Backer G., and Faergeman O. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention Eur Heart J 19 1998 1434 1503
3. De Backer G., Ambrosioni E., and Botch Johnsen K. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts) Eur J Cardiavasc Prev Rehabil 10 Suppl 1 2003 S1 S78
4. Pearson T.A., Laurora I., Chu C., and Kafonek S. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals Arch Intern Med 160 2000 459 467
5. EUROASPIRE II Study Group Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme Eur Heart J 22 2001 554 572
6. Whincup P.H., Emberson J.R., and Lennon L. Low prevalence of lipid lowering drug use in older men with established coronary heart disease Heart 88 2002 25 29
7. Ford E.S., Mokdad A.H., Giles W.H., and Mensah G.A. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: Findings from the National Health and Nutrition Examination Survey, 1999 to 2000 Circulation 107 2003 2185 2189
8. Carswell C.I., Plosker G.L., and Jarvis B. Rosuvastatin Drugs 62 2002 2075 2087
9. Chapman M.J., and McTaggart E. Optimizing the pharmacology of statins: Characteristics of rosuvastatin Atheroscler Suppl 2002 233 237
10. Cheng-Lai A. Rosuvastatin: Anew HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia Heart Dis 5 2003 72 78
11. McTaggart E. Comparative pharmacology of rosuvastatin Atheroscler Suppl 4 2003 9 14
12. Olsson A.G., Istad H., Luurila O. Rosuvastatin Investigators Group Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia Am Heart J 144 2002 1044 1051
13. Brown W.V., Bays H.E., Hassman D.R. Rosuvastatin Study Group Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial Am Heart J 144 2002 1036 1043
14. Schneck D.W., Knopp R.H., and Ballantyne C.M. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholes terolemia and without active arterial disease Am J Cardrol 91 2003 33 41
15. Shepherd J., Hunninghake D.B., and Barter P. Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatinfor achieving lipid-lowering goals Am J Cardiol 91 2003 11C 17C
16. Jones P.H., Davidson M.I.T., Stein E.A. STELLAR Study Group Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial) Am J Cardiol 92 2003 152 160
17. Blasetto J.W., Stein E.A., and Brown W.V. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups Am J Cardiol 91 2003 3C 10C
18. Schuster H., Barter P.L., Stender S. Effective Reductions in Cholesterol Using Rosuvastatin Therapy I Study Group Effects of switching statins on achieve ment of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I)study Am Heart J 147 2004 705 713
19. Cooper K.J., Martin P.D., and Dane A.L. Effect of itraconazole on the pharmacokinetics of rosuvastatin Clin Pharmacol Ther 73 2003 322 329
20. Cooper K.J., Martin P.D., and Dane A.L. The effect of erythromycin on the pharmacokinetics of rosuvastatin Eur J Clin Pharmacol 59 2003 51 56
21. Williams D., and Feely J. Pharmacokinetic-phammacodynamic drug interactions with HMG-CoA reductase inhibitors Clin Pharmacohinet 41 2002 343 370
22. Marcelino J.J., and Feingold K.R. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers Am J Med 100 1996 605 610
23. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultra-centrifuge Clin Chem 18 1972 499 502
24. Schuster H., and Fox J.C. Investigating cardiovascular risk reduction-the Rosuvastatin GALAXY Programme Expert Opin Pharmacother 5 2004 1187 1200
25. Ebrahim S., Davey Smith G., and McCabe C. What role for statins? A review and economic model Health Technol Assess 3 1999 1 91
26. Law M.R., Wald N.J., and Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease and stroke: Systematic review and meta-analysis BMJ 326 2003 1423
27. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A ran domised placebo-controlled trial Lancet 360 2002 7 22
28. Strandberg T.E., and Vanhanen H. Long standing heart disease should be better screened BMJ 321 2000 1083 1084
29. Stein E.A., Strutt K., Southworth H. HeFH Study Group Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia Am J Cardiol 92 2003 1287 1293
30. Hunninghake D.B., Stein E.A., and Bays H.E. Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia Coron Artery Dis 15 2004 115 123
31. Pasternak R.C., Smith S.C. Jr, Bairey-Merz C.N. American College of Cardiology, American Heart Association, and National Heart, Lung, and Blood Institute ACC/AHA/NHLBI Clinical advisory on the use and safety of statins Circulation 106 2002 1024 1028
32. Ballantyne C.M., Corsini A., and Davidson M.H. Risk for myopathy with statin therapy in high-risk patients Arch Intern Med 163 2003 553 564
33. Staffa J.A., Chang J., and Green L. Cerivastatin and reports of fatal rhabdomyolysis N Engl J Med 7 2002 539 540
34. Newman C.B., Palmer G., Silbershatz H., and Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients Am J Cardiol 92 2003 670 676
35. Brewer H.B. Jr Benefit-risk assessment of rosuvastatin 10 to 40 milligrams Am J Cardiol 92 2003 23K 29K
36. Crestor [prescribing Information]. Wilmington, Del:AstraZeneca Pharmaceuticals; 2003.
37. Vidt D.G., Cressman M.D., and Harris S. Rosuvastatin-induced arrest in progression of renal disease Cardiology 102 2004 52 60